Sun Pharma Advanced Research Co
134.32
+0.63(+0.47%)
Market Cap₹4,358.68 Cr
PE Ratio-16.18
IndustryHealthcare
Company Performance:
1D+0.47%
1M+0.60%
6M-4.22%
1Y-1.98%
5Y-25.83%
View Company Insightsright
More news about Sun Pharma Advanced Research Co
13Jan 26
SPARC Advances Clinical Pipeline with Two Priority Programs Showing Progress
SPARC reported strong progress on its two priority clinical programs during its January 08, 2026 R&D Day call. SCD-153 for alopecia areata has completed Phase 1 and enrolled patients in Phase 1B with interim results expected Q4 2026. SBO-154 cancer ADC has initiated Phase 1 dose escalation across multiple geographies with MTD identification targeted for Q3 2026. The company achieved ₹83.25 crores in annual fixed cost savings while maintaining core competencies and received favorable court ruling on its pediatric rare disease voucher claim potentially worth over ₹830 crores.
 no imag found
09Jan 26
SPARC Targets $10 Million Cost Savings Through R&D Consolidation and Workforce Optimization
Sun Pharma Advanced Research Company is implementing a $10 million annual cost-saving strategy through operational consolidation in Vadodara, reducing workforce by 40% to 246 employees by FY27, and cutting R&D spend to $14.30 million. The company is focusing on high-value oncology and immunology assets, with lead candidates SBO-154 and SCD-153 advancing in clinical trials, expecting key results by 2026 while managing $46 million in debt.
 no imag found
20Nov 25
SPARC Resubmits Complete Response Letter for PDP-716 NDA to FDA
Sun Pharma Advanced Research Co (SPARC) has resubmitted a Complete Response Letter to the FDA for its New Drug Application of PDP-716, a novel ophthalmic suspension. The resubmission addresses facility inspection issues raised in a previous FDA communication from July 2023, which did not question the drug's safety or efficacy. PDP-716 is a once-daily brimonidine tartrate 0.35% suspension developed using SPARC's TearAct™ technology. The company will update stakeholders after the FDA determines the completeness of the response.
 no imag found
13Nov 25
SPARC Streamlines R&D Operations: Consolidates Labs in Baroda
Sun Pharma Advanced Research Co (SPARC) is restructuring its R&D operations by consolidating laboratories from multiple locations into two sites in Baroda. The move aims to streamline operations, enhance efficiency, reduce cycle times, and accelerate pipeline development. R&D facilities from Mumbai and Baroda will be integrated into Savli and Tandalja sites in Baroda, while corporate operations remain in Mumbai. The transition, expected to complete by the end of FY26, may involve outsourcing some R&D activities and streamlining the workforce. SPARC assures that current pipeline prioritization and scale will not be affected.
 no imag found
11Nov 25
Sun Pharma Advanced Research Reports Widening Losses in Q2 FY26
Sun Pharma Advanced Research Co (SPARC) reported a net loss of ₹75.97 crore in Q2 FY26, up 46% from the previous quarter. Revenue from operations declined 18.5% to ₹7.86 crore. For H1 FY26, cumulative loss increased to ₹128.00 crore with revenue at ₹17.50 crore. Despite ongoing losses, SPARC maintains its status as a going concern, supported by its promoter group. The company continues to focus on pharmaceutical R&D, reflecting the sector's high-risk, high-reward nature.
 no imag found
10Nov 25
SPARC Reports Narrowed Q2 Loss Despite Revenue Decline
Sun Pharma Advanced Research Co (SPARC) reported Q2 FY2026 results with a 29% reduction in net loss to ₹760 million, down from ₹1,070 million in Q2 FY2025. However, revenue declined 38.3% to ₹79 million from ₹128 million. EBITDA loss improved by 53.3% to ₹429 million, and EPS improved to ₹(1.60) from ₹(2.96). The results show improved cost management but highlight challenges in revenue generation.
 no imag found
04Aug 25
SPARC Reports Narrower Net Loss in Q1 Despite Revenue Decline
Sun Pharma Advanced Research Co (SPARC) reported Q1 financial results with a reduced net loss of ₹518.70 crore, down from ₹959.00 crore in the previous year, despite a 42.70% revenue decline to ₹96.40 crore. Total expenses decreased to ₹705.90 crore from ₹1,138.70 crore. The company recorded other income of ₹91.40 crore. Key expenses included employee benefits (₹313.20 crore), clinical trials (₹55.40 crore), professional charges (₹100.70 crore), and finance costs (₹61.90 crore). SPARC operates in the Pharmaceutical Research and Development segment and maintains its 'Going Concern' status with support from its promoter group entity.
 no imag found
04Jun 25
SPARC Shares Plummet 19% as Psoriasis Drug Fails Phase 2 Trials
Sun Pharma Advanced Research Company (SPARC) experienced a 19% drop in share price following the announcement that its experimental psoriasis treatment failed to meet objectives in Phase 2 clinical trials. This setback highlights the risks associated with drug development in the pharmaceutical industry and represents a significant challenge for SPARC's research pipeline.
 no imag found
04Jun 25
Sun Pharma Advanced Research Company: Psoriasis Drug Fails Phase 2 Trials, Shares Plummet
Sun Pharma Advanced Research Company (SPARC) has discontinued its investigational drug SCD-044 (Vibozilimod) for psoriasis and atopic dermatitis treatment after Phase 2 clinical trials failed to meet primary endpoints. The company's stock price dropped 20% to Rs 156.50 on the BSE following the announcement. This setback impacts SPARC's specialty pipeline and may lead to a reassessment of the company's drug development strategy.
 no imag found
12May 25
Sun Pharma Advanced Research to Discuss Fund Raising Proposal in Upcoming Board Meeting
Sun Pharma Advanced Research Company (SPARC) has announced a board meeting on May 19, 2023, to discuss and potentially approve a fund-raising proposal. While specific details are not yet disclosed, this initiative could significantly impact the company's financial strategy and future operations. Possible uses for the funds in the pharmaceutical sector typically include research and development, clinical trials, infrastructure expansion, debt reduction, or working capital enhancement.
 no imag found
31Mar 25
SPARC Advances Cancer Treatment: IND Application for SBO-154 Submitted to FDA
Sun Pharma Advanced Research Company (SPARC) has submitted an Investigational New Drug (IND) application for SBO-154 to the U.S. FDA. SBO-154 is an antibody-drug conjugate targeting MUC1 for advanced solid tumor treatment. The company plans to initiate global Phase 1 clinical trials, including dose-escalation and expansion phases, to evaluate the drug's safety and efficacy. This marks a significant milestone in SPARC's oncology pipeline development.
 no imag found
1 Year Returns:-1.98%
Industry Peers
Sun Pharmaceutical
1,717.10
(+0.98%)
Divis Laboratories
6,187.50
(+0.62%)
Torrent Pharmaceuticals
4,258.40
(-0.07%)
Cipla
1,343.90
(-0.92%)
Dr Reddys Laboratories
1,284.80
(+1.21%)
Lupin
2,247.50
(+1.17%)
Zydus Life Science
906.65
(-0.42%)
Mankind Pharma
2,062.90
(-0.98%)
Aurobindo Pharma
1,186.70
(+0.18%)
Alkem Laboratories
5,456.50
(-0.44%)